2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases

Essam A. Sheta, Stanley H. Appel, Ira L. Goldknopf

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

This review addresses the challenges of neuroproteomics and recent progress in biomarkers and tests for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. The review will discuss how the application of quantitative 2D gel electrophoresis, combined with appropriate single-variable and multivariate biostatistics, allows for selection of disease-specific serum biomarkers. It will also address how the use of large cohorts of specifically targeted patient blood serum samples and complimentary age-matched controls, in parallel with the use of selected panels of these biomarkers, are being applied to the development of blood tests to specifically address unmet pressing needs in the differential diagnosis of these diseases, and to provide potential avenues for mechanism-based drug targeting and treatment monitoring. While exploring recent findings in this area, the review discusses differences in critical pathways of immune/inflammation and amyloid formation between Parkinson's disease and amyotrophic lateral sclerosis, as well as discernable synergistic relationships between these pathways that are revealed by this approach. The potential for pathway measurement in blood tests for differential diagnosis, disease burden and therapeutic monitoring is also outlined.

Original languageEnglish (US)
Pages (from-to)45-62
Number of pages18
JournalExpert Review of Proteomics
Volume3
Issue number1
DOIs
StatePublished - Jul 7 2006

Keywords

  • 2D
  • ALS
  • Alzheimer's
  • Biomarkers
  • Biostatistics
  • Inflammation
  • Multivariate
  • Neurodegenerative
  • Parkinson's
  • Proteomics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Biotechnology

Fingerprint Dive into the research topics of '2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases'. Together they form a unique fingerprint.

Cite this